Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.
Who will be affected?
Readers: No access to all 28 journals. We recommend accessing our articles via PubMed Central
Authors: No access to the submission form or your user account.
Reviewers: No access to your user account. Please download manuscripts you are reviewing for offline reading before Wednesday, July 01, 2020 at 7:00 PM.
Editors: No access to your user account to assign reviewers or make decisions.
Copyeditors: No access to user account. Please download manuscripts you are copyediting before Wednesday, July 01, 2020 at 7:00 PM.
Rabade Castedo C, Estany-Gestal A, Jiménez Ruiz CA, de Granda-Orive JI, Riesco-Miranda JA, Cristóbal Fernández MI, Ramos-Pinedo A, Signes-Costa Miñana J, Gorordo-Unzueta MI, Valido-Morales A, Sellarés -Torres J, Cabrera-César E, Frino-García A, Valdés Cuadrado L
Efficacy, Safety, and Economic Impact of Cytisinicline Maintenance Therapy in Patients Who Are Candidates for Smoking Cessation: Protocol for a Phase IV, Multicenter, Randomized, Open-Label, Controlled, Parallel Clinical Trial (CITISILONG Trial)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Efficacy, safety and economic impact of citisinicline maintenance therapy in patients who are candidates for smoking cessation. Protocol for a phase IV, multicentre, randomised, open-label, controlled, parallel, multicentre clinical trial. CITISILONG trial
Carlos Rabade Castedo;
Ana Estany-Gestal;
Carlos A Jiménez Ruiz;
José Ignacio de Granda-Orive;
Juan Antonio Riesco-Miranda;
María Isabel Cristóbal Fernández;
Angela Ramos-Pinedo;
Jaime Signes-Costa Miñana;
María Inmaculada Gorordo-Unzueta;
Agustin Valido-Morales;
Jacobo Sellarés -Torres;
Eva Cabrera-César;
Alejandro Frino-García;
Luis Valdés Cuadrado
ABSTRACT
Background:
Cytisynicline has proven to be an effective, efficient and safe molecule in smoking cessation. However, the established 25-day regimen could be insufficient in a high percentage of smokers, so it is necessary to study maintained therapies of this drug.
Objective:
To compare the efficacy of the cytisinicline regimen used in routine clinical practice with two maintained regimens of 50 and 75 days, respectively. In addition, the safety and economic impact of each regimen will be determined.
Methods:
A prospective, multicentre, open-label, controlled, parallel, phase IV clinical trial of 402 smoker patients prepared to quit smoking. Participants will be randomised to three groups in a 1:1:1 ratio, to receive cytisynicline in a clinical practice regimen (25 days) or cytisynicline in a maintained regimen (50 and 75 days respectively). The study was conducted in 10 hospitals in Spain
Results:
Recruitment for the trial and patient enrolment will be completed in May 2026. Follow-up of all participants will extend to June 2027.
Conclusions:
In conclusion, this study evaluates the optimisation of cytisinicline in daily clinical practice, increasing the benefits of its pharmaceutical properties without affecting patient safety. Clinical Trial: European Clinical Trials Register with EUDRACT code 2024-518936-36-00.
Citation
Please cite as:
Rabade Castedo C, Estany-Gestal A, Jiménez Ruiz CA, de Granda-Orive JI, Riesco-Miranda JA, Cristóbal Fernández MI, Ramos-Pinedo A, Signes-Costa Miñana J, Gorordo-Unzueta MI, Valido-Morales A, Sellarés -Torres J, Cabrera-César E, Frino-García A, Valdés Cuadrado L
Efficacy, Safety, and Economic Impact of Cytisinicline Maintenance Therapy in Patients Who Are Candidates for Smoking Cessation: Protocol for a Phase IV, Multicenter, Randomized, Open-Label, Controlled, Parallel Clinical Trial (CITISILONG Trial)